REGENXBIO Inc. Research and Development Expense
REGENXBIO Inc. (RGNX) reported Research and Development Expense of $56.09 million for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-06.
Financial Statements › Expense Statement › Operating Expenses
us-gaap:ResearchAndDevelopmentExpense · last filed 2026-08-06
- REGENXBIO Inc. research and development expense for the quarter ending 2026-06-30 was $56.09M, a 5.74% decline year-over-year.
- REGENXBIO Inc. research and development expense for the quarter ending 2026-03-31 was $57.34M, a 8.01% increase year-over-year.
- REGENXBIO Inc. research and development expense for the quarter ending 2025-12-31 was $59.61M, a 18.32% increase year-over-year.
- REGENXBIO Inc. research and development expense for the quarter ending 2025-09-30 was $56.10M, a 3.07% increase year-over-year.
- REGENXBIO Inc. research and development expense for fiscal 2025 was $228.30M, a 9.48% increase from fiscal 2024.
- REGENXBIO Inc. research and development expense for fiscal 2024 was $208.52M, a 10.22% decline from fiscal 2023.
- REGENXBIO Inc. research and development expense for fiscal 2023 was $232.27M, a 4.20% decline from fiscal 2022.
- REGENXBIO Inc. research and development expense for fiscal 2022 was $242.45M, a 33.63% increase from fiscal 2021.
| Period end | Research and Development Expense 3 month | Research and Development Expense 6 month | Research and Development Expense 9 month | Research and Development Expense 12 month |
|---|---|---|---|---|
| 2026-06-30 | $56.09M 10-Q · filed 2026-08-06 | $113.42M 10-Q · filed 2026-08-06 | $173.04M derived: sum of 3 quarters · filed 2026-08-06 | $229.14M derived: sum of 4 quarters · filed 2026-08-06 |
| 2026-03-31 | $57.34M 10-Q · filed 2026-05-14 | $116.95M derived: sum of 2 quarters · filed 2026-05-14 | $173.05M derived: sum of 3 quarters · filed 2026-05-14 | $232.55M derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-12-31 | $59.61M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-05 | $115.71M derived: sum of 2 quarters · filed 2026-03-05 | $175.21M derived: sum of 3 quarters · filed 2026-08-06 | $228.30M 10-K · filed 2026-03-05 |
| 2025-09-30 | $56.10M 10-Q · filed 2025-11-06 | $115.60M derived: sum of 2 quarters · filed 2026-08-06 | $168.69M 10-Q · filed 2025-11-06 | $219.07M derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-06-30 | $59.50M 10-Q · filed 2026-08-06 | $112.59M 10-Q · filed 2026-08-06 | $162.97M derived: sum of 3 quarters · filed 2026-08-06 | $217.40M derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-03-31 | $53.09M 10-Q · filed 2026-05-14 | $103.47M derived: sum of 2 quarters · filed 2026-05-14 | $157.90M derived: sum of 3 quarters · filed 2026-05-14 | $206.76M derived: sum of 4 quarters · filed 2026-05-14 |
| 2024-12-31 | $50.38M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-05 | $104.81M derived: sum of 2 quarters · filed 2026-03-05 | $153.68M derived: sum of 3 quarters · filed 2026-03-05 | $208.52M 10-K · filed 2026-03-05 |
| 2024-09-30 | $54.43M 10-Q · filed 2025-11-06 | $103.30M derived: sum of 2 quarters · filed 2025-11-06 | $158.14M 10-Q · filed 2025-11-06 | $213.82M derived: sum of 4 quarters · filed 2025-11-06 |
| 2024-06-30 | $48.87M 10-Q · filed 2025-08-07 | $103.71M 10-Q · filed 2025-08-07 | $159.39M derived: sum of 3 quarters · filed 2025-08-07 | $217.58M derived: sum of 4 quarters · filed 2025-08-07 |
| 2024-03-31 | $54.84M 10-Q · filed 2025-05-12 | $110.53M derived: sum of 2 quarters · filed 2025-05-12 | $168.71M derived: sum of 3 quarters · filed 2025-05-12 | $228.59M derived: sum of 4 quarters · filed 2025-05-12 |
| 2023-12-31 | $55.68M derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-13 | $113.86M derived: sum of 2 quarters · filed 2025-03-13 | $173.75M derived: sum of 3 quarters · filed 2025-03-13 | $232.27M 10-K · filed 2025-03-13 |
| 2023-09-30 | $58.18M 10-Q · filed 2024-11-06 | $118.07M derived: sum of 2 quarters · filed 2024-11-06 | $176.59M 10-Q · filed 2024-11-06 | $239.09M derived: sum of 4 quarters · filed 2025-03-13 |
| 2023-06-30 | $59.89M 10-Q · filed 2024-08-01 | $118.40M 10-Q · filed 2024-08-01 | $180.91M derived: sum of 3 quarters · filed 2025-03-13 | $244.22M derived: sum of 4 quarters · filed 2025-03-13 |
| 2023-03-31 | $58.52M 10-Q · filed 2024-05-08 | $121.02M derived: sum of 2 quarters · filed 2025-03-13 | $184.33M derived: sum of 3 quarters · filed 2025-03-13 | $245.34M derived: sum of 4 quarters · filed 2025-03-13 |
| 2022-12-31 | $62.51M derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-13 | $125.82M derived: sum of 2 quarters · filed 2025-03-13 | $186.83M derived: sum of 3 quarters · filed 2025-03-13 | $242.45M 10-K · filed 2025-03-13 |
| 2022-09-30 | $63.31M 10-Q · filed 2023-11-08 | $124.32M derived: sum of 2 quarters · filed 2023-11-08 | $179.95M 10-Q · filed 2023-11-08 | $227.93M derived: sum of 4 quarters · filed 2024-02-27 |
| 2022-06-30 | $61.01M 10-Q · filed 2023-08-02 | $116.64M 10-Q · filed 2023-08-02 | $164.61M derived: sum of 3 quarters · filed 2024-02-27 | $212.47M derived: sum of 4 quarters · filed 2024-02-27 |
| 2022-03-31 | $55.63M 10-Q · filed 2023-05-03 | $103.61M derived: sum of 2 quarters · filed 2024-02-27 | $151.46M derived: sum of 3 quarters · filed 2024-02-27 | $197.34M derived: sum of 4 quarters · filed 2024-02-27 |
| 2021-12-31 | $47.98M derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-27 | $95.83M derived: sum of 2 quarters · filed 2024-02-27 | $141.72M derived: sum of 3 quarters · filed 2024-02-27 | $181.44M 10-K · filed 2024-02-27 |
| 2021-09-30 | $47.85M 10-Q · filed 2022-11-03 | $93.74M derived: sum of 2 quarters · filed 2022-11-03 | $133.46M 10-Q · filed 2022-11-03 | $180.64M derived: sum of 4 quarters · filed 2022-11-03 |
| 2021-06-30 | $45.88M 10-Q · filed 2022-08-03 | $85.60M 10-Q · filed 2022-08-03 | $132.78M derived: sum of 3 quarters · filed 2022-08-03 | $176.75M derived: sum of 4 quarters · filed 2022-08-03 |
| 2021-03-31 | $39.72M 10-Q · filed 2022-05-04 | $86.90M derived: sum of 2 quarters · filed 2022-05-04 | $130.87M derived: sum of 3 quarters · filed 2022-05-04 | $168.98M derived: sum of 4 quarters · filed 2022-05-04 |
| 2020-12-31 | $47.18M 10-K · filed 2021-03-01 | $91.15M derived: sum of 2 quarters · filed 2021-11-02 | $129.26M derived: sum of 3 quarters · filed 2021-11-02 | $166.29M 10-K · filed 2023-02-28 |
| 2020-09-30 | $43.97M 10-Q · filed 2021-11-02 | $82.08M derived: sum of 2 quarters · filed 2021-11-02 | $119.11M 10-Q · filed 2021-11-02 | $152.92M derived: sum of 4 quarters · filed 2021-11-02 |
| 2020-06-30 | $38.11M 10-Q · filed 2021-08-09 | $75.15M 10-Q · filed 2021-08-09 | $108.95M derived: sum of 3 quarters · filed 2021-08-09 | $144.65M derived: sum of 4 quarters · filed 2021-08-09 |
| 2020-03-31 | $37.03M 10-Q · filed 2021-05-05 | $70.84M derived: sum of 2 quarters · filed 2021-05-05 | $106.53M derived: sum of 3 quarters · filed 2021-05-05 | $136.02M derived: sum of 4 quarters · filed 2021-05-05 |
| 2019-12-31 | $33.81M 10-K · filed 2021-03-01 | $69.50M derived: sum of 2 quarters · filed 2021-03-01 | $98.98M derived: sum of 3 quarters · filed 2021-03-01 | $124.19M 10-K · filed 2022-03-01 |
| 2019-09-30 | $35.69M 10-K · filed 2021-03-01 | $65.17M derived: sum of 2 quarters · filed 2021-03-01 | $90.38M 10-Q · filed 2020-11-04 | $114.71M derived: sum of 4 quarters · filed 2021-03-01 |
| 2019-06-30 | $29.48M 10-K · filed 2021-03-01 | $54.69M 10-Q · filed 2020-08-06 | $79.02M derived: sum of 3 quarters · filed 2021-03-01 | $97.52M derived: sum of 4 quarters · filed 2021-03-01 |
| 2019-03-31 | $25.20M 10-K · filed 2021-03-01 | $49.53M derived: sum of 2 quarters · filed 2021-03-01 | $68.04M derived: sum of 3 quarters · filed 2021-03-01 | $89.53M derived: sum of 4 quarters · filed 2021-03-01 |
| 2018-12-31 | $24.33M 10-K · filed 2020-02-26 | $42.84M derived: sum of 2 quarters · filed 2020-02-26 | $64.32M derived: sum of 3 quarters · filed 2020-02-26 | $83.87M 10-K · filed 2021-03-01 |
| 2018-09-30 | $18.51M 10-K · filed 2020-02-26 | $39.99M derived: sum of 2 quarters · filed 2020-02-26 | $59.54M 10-Q · filed 2019-11-05 | $73.71M derived: sum of 4 quarters · filed 2020-02-26 |
| 2018-06-30 | $21.49M 10-K · filed 2020-02-26 | $41.04M 10-Q · filed 2019-08-07 | $55.21M derived: sum of 3 quarters · filed 2020-02-26 | $67.72M derived: sum of 4 quarters · filed 2020-02-26 |
| 2018-03-31 | $19.55M 10-K · filed 2020-02-26 | $33.72M derived: sum of 2 quarters · filed 2020-02-26 | $46.24M derived: sum of 3 quarters · filed 2020-02-26 | $60.16M derived: sum of 4 quarters · filed 2020-02-26 |
| 2017-12-31 | $14.17M 10-K · filed 2019-02-27 | $26.69M derived: sum of 2 quarters · filed 2019-02-27 | $40.60M derived: sum of 3 quarters · filed 2019-02-27 | $57.22M 10-K · filed 2020-02-26 |
| 2017-09-30 | $12.52M 10-K · filed 2019-02-27 | $26.43M derived: sum of 2 quarters · filed 2019-02-27 | $43.05M 10-Q · filed 2018-11-07 | $59.11M derived: sum of 4 quarters · filed 2019-02-27 |
| 2017-06-30 | $13.92M 10-K · filed 2019-02-27 | $30.54M 10-Q · filed 2018-08-08 | $46.59M derived: sum of 3 quarters · filed 2019-02-27 | $59.16M derived: sum of 4 quarters · filed 2019-02-27 |
| 2017-03-31 | $16.62M 10-K · filed 2019-02-27 | $32.68M derived: sum of 2 quarters · filed 2019-02-27 | $45.24M derived: sum of 3 quarters · filed 2019-02-27 | $55.92M derived: sum of 4 quarters · filed 2019-02-27 |
| 2016-12-31 | $16.06M 10-K · filed 2018-03-06 | $28.62M derived: sum of 2 quarters · filed 2018-03-06 | $39.30M derived: sum of 3 quarters · filed 2018-03-06 | $45.48M 10-K · filed 2019-02-27 |
| 2016-09-30 | $12.56M 10-K · filed 2018-03-06 | $23.24M derived: sum of 2 quarters · filed 2018-03-06 | $29.42M 10-Q · filed 2017-11-08 | $34.23M derived: sum of 4 quarters · filed 2018-03-06 |
| 2016-06-30 | $10.68M 10-K · filed 2018-03-06 | $16.86M 10-Q · filed 2017-08-08 | $21.68M derived: sum of 3 quarters · filed 2018-03-06 | $27.34M derived: sum of 4 quarters · filed 2018-03-06 |
| 2016-03-31 | $6.18M 10-K · filed 2018-03-06 | $10.99M derived: sum of 2 quarters · filed 2018-03-06 | $16.66M derived: sum of 3 quarters · filed 2018-03-06 | $20.67M derived: sum of 4 quarters · filed 2018-03-06 |
| 2015-12-31 | $4.81M 10-K · filed 2017-03-07 | $10.48M derived: sum of 2 quarters · filed 2017-03-07 | $14.49M derived: sum of 3 quarters · filed 2017-03-07 | $17.28M 10-K · filed 2018-03-06 |
| 2015-09-30 | $5.66M 10-K · filed 2017-03-07 | $9.68M derived: sum of 2 quarters · filed 2017-03-07 | $12.47M 10-Q · filed 2016-11-09 | $14.56M derived: sum of 4 quarters · filed 2017-03-07 |
| 2015-06-30 | $4.01M 10-K · filed 2017-03-07 | $6.80M 10-Q · filed 2016-08-09 | $8.89M derived: sum of 3 quarters · filed 2017-03-07 | $9.98M derived: sum of 4 quarters · filed 2017-03-07 |
| 2015-03-31 | $2.79M 10-K · filed 2017-03-07 | $4.88M derived: sum of 2 quarters · filed 2017-03-07 | $5.97M derived: sum of 3 quarters · filed 2017-03-07 | |
| 2014-12-31 | $2.09M derived: 10-K 12 month − 10-Q 9 month · filed 2017-03-07 | $3.18M derived: sum of 2 quarters · filed 2017-03-07 | $4.96M 10-K · filed 2017-03-07 | |
| 2014-09-30 | $1.08M 10-Q · filed 2015-11-05 | $2.87M 10-Q · filed 2015-11-05 | ||
| 2013-12-31 | $5.05M 10-K · filed 2016-03-03 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Entera Bio Ltd. (ENTX) | $0.485B | ||
| Tectonic Therapeutic, Inc. (TECX) | United States | $0.469B | -7.68 |
| Autolus Therapeutics plc (AUTL) | $0.506B | -1.52 | |
| Eikon Therapeutics, Inc. (EIKN) | United States | $0.446B | |
| Kyverna Therapeutics, Inc. (KYTX) | United States | $0.434B | -3.60 |
| Editas Medicine, Inc. (EDIT) | United States | $0.424B | -4.29 |
| Scribe Therapeutics, Inc. (SCTX) | United States | $0.410B | |
| Prime Medicine, Inc. (PRME) | United States | $0.557B | -3.54 |
| Zura Bio Ltd (ZURA) | $0.398B | -6.56 | |
| Surrozen, Inc./DE (SRZN) | United States | $0.395B |